Back to Agenda
S34 : How should be Reguratory Document for Innovative Drug Development and Effective Drug Application Review in Society 5.0 Era?
Session Chair(s)
Kazuhiko Mori, PhD, MSc
Senior Managing Director
Japan Pharmaceutical Manufacturers Association (JPMA), Japan
Speaker(s)
How should be Regulatory Document for Innovative Drug Development and Effective Drug Application Review in Society 5.0 Era?
Tsuyoshi Ishiki
Eli Lilly Japan K.K., Japan
Global Scientific Communications Japan -
Yuki Ando, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Principal Senior Scientist for Biostatistics
Initiatives and Challenges in Generative AI Utilization
Kazumitsu Kanatani
Chugai Pharmaceutical Co., Ltd., Japan
Head, Digital Strategy Dept, Digital Transformation Unit.
Utilization of Accumulus Synergy and Expectation from Pharmaceutical Campany
Takayuki Imaeda, MPharm, MS
Pfizer R&D Japan, Japan
Head of Regulatory Sciences
Mamoru Narukawa, PhD, RPh
Kitasato University School of Pharmacy , Japan
Professor, Department of Clinical Medicine (Pharmaceutical Medicine)
Have an account?